Because the tyrosine kinase domains of ROS1 and NTRK share structural similarity with that of ALK and multiple ALK inhibitors exert inhibitory effects on ROS1 and NTRK kinase activity, we assessed the efficacy of gilteritinib against ROS1 or NTRK fusion using cancer cell lines and Ba/F3 models. Here, ROS1 is linked to cancer.